Immix Biopharma (IMMX) Financials

Immix Biopharma logo
$7.03 -0.01 (-0.16%)
As of 02:36 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Immix Biopharma

Annual Income Statements for Immix Biopharma

This table shows Immix Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-2.21 -24 -8.23 -15 -22 -29
Consolidated Net Income / (Loss)
-1.15 -24 -8.23 -16 -22 -29
Net Income / (Loss) Continuing Operations
-2.28 -24 -8.23 -16 -22 -29
Total Pre-Tax Income
-1.13 -24 -8.22 -16 -22 -29
Total Operating Income
-0.45 -1.35 -8.22 -16 -23 -30
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
0.91 1.35 8.22 16 23 30
Selling, General & Admin Expense
0.21 1.23 4.02 7.41 11 14
Research & Development Expense
0.25 0.13 4.20 8.74 11 16
Total Other Income / (Expense), net
-1.35 -23 -0.00 0.57 1.02 0.56
Interest & Investment Income
- - 0.00 0.57 1.02 0.56
Income Tax Expense
0.02 0.01 0.01 0.03 0.04 0.04
Net Income / (Loss) Attributable to Noncontrolling Interest
- - 0.00 -0.17 -0.08 0.00
Basic Earnings per Share
($0.34) ($6.64) ($0.59) ($0.89) ($0.76) ($0.89)
Weighted Average Basic Shares Outstanding
3.38M 3.67M 13.89M 17.34M 28.29M 32.97M
Diluted Earnings per Share
($0.34) - ($0.59) ($0.89) ($0.76) ($0.89)
Weighted Average Diluted Shares Outstanding
3.38M 13.86M 13.89M 17.34M 28.29M 32.97M
Weighted Average Basic & Diluted Shares Outstanding
3.38M 13.86M 13.90M 26.40M 27.72M 52.96M

Quarterly Income Statements for Immix Biopharma

This table shows Immix Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - - 7.66 - - - 16
Net Income / (Loss) Attributable to Common Shareholders
-5.26 -4.39 -7.15 -4.81 -4.53 -6.62 -7.59 -11 -10 -12 -14
Consolidated Net Income / (Loss)
-5.33 -4.41 -7.15 -4.81 -4.54 -6.62 -7.59 -11 -10 -12 -14
Net Income / (Loss) Continuing Operations
-5.33 -4.41 -7.15 -4.81 -4.54 -6.62 -7.59 -11 -10 -12 -14
Total Pre-Tax Income
-5.32 -4.40 -7.14 -4.80 -4.53 -6.61 -7.58 -11 -10 -12 -14
Total Operating Income
-5.59 -4.70 -7.39 -4.99 -4.68 -6.72 -7.66 -11 -11 -12 -16
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
5.59 4.70 7.39 4.99 4.68 6.72 7.66 11 11 12 16
Selling, General & Admin Expense
2.34 2.48 2.95 3.61 2.71 2.75 3.08 5.17 4.82 7.12 10
Research & Development Expense
3.25 2.22 4.45 1.37 1.98 3.97 4.58 5.73 5.98 5.33 5.54
Total Other Income / (Expense), net
0.27 0.31 0.26 0.19 0.15 0.10 0.08 0.22 0.72 0.91 2.02
Interest & Investment Income
0.27 0.31 0.26 0.19 0.15 0.10 0.08 0.22 0.72 0.91 2.02
Income Tax Expense
0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.00
Basic Earnings per Share
($0.22) ($0.15) ($0.24) ($0.15) ($0.15) ($0.22) ($0.24) ($0.28) ($0.18) ($0.18) ($0.19)
Weighted Average Basic Shares Outstanding
23.44M 28.79M 29.42M 28.29M 29.70M 29.98M 31.93M 32.97M 55.37M 63.77M 74.09M
Diluted Earnings per Share
($0.22) ($0.15) ($0.24) ($0.15) ($0.15) ($0.22) ($0.24) ($0.28) ($0.18) ($0.18) ($0.19)
Weighted Average Diluted Shares Outstanding
23.44M 28.79M 29.42M 28.29M 29.70M 29.98M 31.93M 32.97M 55.37M 63.77M 74.09M
Weighted Average Basic & Diluted Shares Outstanding
26.41M 27.45M 27.51M 27.72M 27.88M 28.83M 33.58M 52.96M 54.41M 71.54M 83.81M

Annual Cash Flow Statements for Immix Biopharma

This table details how cash moves in and out of Immix Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-0.34 17 -4.21 4.07 0.17 76
Net Cash From Operating Activities
-0.40 -1.59 -7.41 -11 -15 -24
Net Cash From Continuing Operating Activities
-0.40 -1.59 -7.41 -11 -15 -24
Net Income / (Loss) Continuing Operations
-1.15 -24 -8.23 -16 -22 -29
Consolidated Net Income / (Loss)
-1.15 -24 -8.23 -16 -22 -29
Depreciation Expense
0.00 0.00 0.00 0.01 0.03 0.25
Amortization Expense
0.00 0.06 - 0.00 0.08 0.12
Non-Cash Adjustments To Reconcile Net Income
0.58 23 0.62 2.57 3.02 2.44
Changes in Operating Assets and Liabilities, net
0.17 -0.39 0.20 1.65 3.97 2.70
Net Cash From Investing Activities
0.00 -0.00 0.00 -0.05 -1.18 -7.21
Net Cash From Continuing Investing Activities
0.00 -0.00 0.00 -0.05 -1.18 -7.21
Purchase of Property, Plant & Equipment
0.00 -0.00 0.00 -0.05 -1.18 -0.73
Purchase of Investments
- - - - 0.00 -6.48
Net Cash From Financing Activities
0.00 19 3.23 15 16 107
Net Cash From Continuing Financing Activities
0.00 19 3.23 15 16 107
Repurchase of Common Equity
- 0.00 -0.11 -0.23 0.00 -0.14
Issuance of Common Equity
0.00 19 2.91 16 16 107
Other Financing Activities, net
- - 0.48 0.18 0.00 0.13
Effect of Exchange Rate Changes
0.06 -0.01 -0.03 0.03 -0.00 0.00
Cash Interest Paid
0.00 0.00 0.01 0.00 0.00 0.00
Cash Income Taxes Paid
0.02 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Immix Biopharma

This table details how cash moves in and out of Immix Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
12 -5.34 -4.28 -2.01 -1.76 -4.28 4.31 78 -15 146 95
Net Cash From Operating Activities
-3.83 -5.26 -4.04 -1.48 -1.69 -5.31 -5.91 -11 -9.83 -12 -12
Net Cash From Continuing Operating Activities
-3.83 -5.26 -4.04 -1.48 -1.69 -5.31 -5.91 -11 -9.83 -12 -12
Net Income / (Loss) Continuing Operations
-5.33 -4.41 -7.15 -4.81 -4.54 -6.62 -7.59 -11 -10 -12 -14
Consolidated Net Income / (Loss)
-5.33 -4.41 -7.15 -4.81 -4.54 -6.62 -7.59 -11 -10 -12 -14
Depreciation Expense
0.00 0.00 0.01 0.02 0.04 0.06 0.10 0.05 0.09 0.09 0.09
Amortization Expense
0.02 0.02 0.02 0.02 0.02 0.02 0.04 0.04 0.04 0.04 0.02
Non-Cash Adjustments To Reconcile Net Income
0.94 0.64 0.73 0.71 0.87 0.53 0.47 0.57 0.60 0.94 1.20
Changes in Operating Assets and Liabilities, net
0.54 -1.51 2.35 2.59 1.93 0.70 1.07 -1.00 -0.47 -1.25 0.30
Net Cash From Investing Activities
-0.30 -0.10 -0.27 -0.51 -0.07 -0.13 -0.37 -6.65 -4.80 2.67 -12
Net Cash From Continuing Investing Activities
-0.30 -0.10 -0.27 -0.51 -0.07 -0.13 -0.37 -6.65 -4.80 2.67 -12
Purchase of Property, Plant & Equipment
-0.30 -0.10 -0.27 -0.51 -0.07 -0.13 -0.37 -0.17 -0.03 -0.02 -0.12
Purchase of Investments
- - - - 0.00 - - - -7.77 -4.55 -15
Sale and/or Maturity of Investments
- - - - 0.00 - - - 3.00 7.24 3.10
Net Cash From Financing Activities
16 - - - 0.00 1.11 11 96 -0.04 155 119
Net Cash From Continuing Financing Activities
16 - - - 0.00 1.11 11 96 -0.04 155 119
Issuance of Common Equity
16 - - -0.00 - 1.11 11 96 - - 103
Other Financing Activities, net
- - - - 0.00 - - - 0.03 0.45 16
Effect of Exchange Rate Changes
-0.01 0.01 0.02 -0.03 -0.01 0.04 -0.02 -0.01 -0.01 0.02 -0.01

Annual Balance Sheets for Immix Biopharma

This table presents Immix Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
0.54 18 15 20 23 105
Total Current Assets
0.53 18 15 20 20 101
Cash & Equivalents
0.39 18 13 18 18 94
Short-Term Investments
- - - - 0.00 6.48
Prepaid Expenses
0.01 0.52 1.21 1.11 0.54 0.83
Plant, Property, & Equipment, net
0.01 0.01 0.00 0.05 1.74 2.52
Total Noncurrent Assets
0.00 0.00 0.01 0.09 1.01 1.08
Long-Term Investments
- - - - - 0.00
Other Noncurrent Operating Assets
- 0.00 0.01 0.09 1.01 1.08
Total Liabilities & Shareholders' Equity
0.54 18 15 20 23 105
Total Liabilities
5.27 0.20 1.75 3.72 9.70 11
Total Current Liabilities
5.27 0.20 1.27 3.72 8.69 10
Accounts Payable
0.25 0.14 1.27 3.72 8.62 9.97
Other Current Liabilities
0.58 - - 0.00 0.07 0.14
Total Noncurrent Liabilities
0.00 0.00 0.48 0.00 1.01 0.93
Capital Lease Obligations
- - - - - 0.93
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-4.73 18 13 16 13 94
Total Preferred & Common Equity
-4.73 18 13 16 13 94
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-4.73 18 13 16 13 94
Common Stock
0.51 48 51 70 88 198
Retained Earnings
-5.37 -30 -38 -53 -75 -104
Treasury Stock
- 0.00 -0.10 -0.10 -0.10 -0.10
Accumulated Other Comprehensive Income / (Loss)
0.13 0.13 0.09 0.13 -0.00 0.06

Quarterly Balance Sheets for Immix Biopharma

This table presents Immix Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
22 34 29 25 20 16 20 96 239 346
Total Current Assets
22 33 27 23 17 12 17 92 234 338
Cash & Equivalents
20 29 24 20 16 12 16 79 225 320
Short-Term Investments
- - - - - - - 11 6.62 16
Prepaid Expenses
2.10 1.57 1.38 1.09 0.86 0.69 0.64 1.70 1.68 1.77
Plant, Property, & Equipment, net
0.04 0.36 0.45 1.36 2.12 2.23 2.36 2.43 2.36 2.41
Total Noncurrent Assets
0.10 1.07 1.05 1.03 0.99 1.08 1.14 1.11 2.96 5.46
Long-Term Investments
- - - - - - - - 2.05 4.57
Other Noncurrent Operating Assets
0.10 1.07 1.05 1.03 0.99 1.08 1.14 1.11 0.91 0.89
Total Liabilities & Shareholders' Equity
22 34 29 25 20 16 20 96 239 346
Total Liabilities
2.83 6.72 4.94 7.59 10 11 12 11 10 11
Total Current Liabilities
2.83 5.66 3.90 6.56 9.31 10 11 11 9.30 10
Accounts Payable
2.83 5.62 3.85 6.50 9.24 9.94 11 10 9.19 9.93
Other Current Liabilities
- 0.03 0.05 0.06 0.07 0.07 0.14 0.13 0.11 0.10
Total Noncurrent Liabilities
0.00 1.06 1.04 1.03 0.99 0.97 0.97 0.91 0.89 0.87
Capital Lease Obligations
- 1.06 1.04 1.03 0.99 0.97 0.97 0.91 0.89 0.87
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
20 28 24 18 9.59 4.65 8.26 84 229 335
Total Preferred & Common Equity
20 28 24 18 9.59 4.65 8.26 84 229 335
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
20 28 24 18 9.59 4.65 8.26 84 229 335
Common Stock
68 87 87 88 89 91 102 199 355 475
Retained Earnings
-48 -59 -63 -70 -80 -86 -94 -115 -126 -140
Treasury Stock
-0.10 -0.10 -0.10 -0.10 -0.10 -0.10 -0.10 -0.10 -0.10 -0.10
Accumulated Other Comprehensive Income / (Loss)
0.05 0.09 0.12 0.19 0.02 0.07 0.06 0.11 0.12 0.01

Annual Metrics And Ratios for Immix Biopharma

This table displays calculated financial ratios and metrics derived from Immix Biopharma's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 0.00 13,927,067.00 19,867,224.00 27,507,637.00 33,577,873.00
DEI Adjusted Shares Outstanding
0.00 0.00 13,927,067.00 19,867,224.00 27,507,637.00 33,577,873.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 0.00 -0.59 -0.78 -0.79 -0.88
Growth Metrics
- - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
0.00% -1,312.71% 65.84% -96.37% -39.81% -31.17%
EBIT Growth
0.00% -1,314.35% 65.91% -96.39% -40.48% -32.11%
NOPAT Growth
0.00% -197.90% -507.90% -96.39% -40.48% -32.11%
Net Income Growth
0.00% -2,024.28% 66.25% -89.50% -39.13% -35.67%
EPS Growth
0.00% 0.00% 0.00% -50.85% 14.61% -17.11%
Operating Cash Flow Growth
0.00% -292.72% -366.13% -53.50% -28.35% -63.96%
Free Cash Flow Firm Growth
0.00% 0.00% -149.85% -102.48% -24.14% -54.70%
Invested Capital Growth
0.00% 159.61% -168.43% -371.78% -239.15% -28.19%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% 0.00% -63.66% -10.85% 1.86% -24.68%
EBIT Q/Q Growth
0.00% 0.00% -63.64% -10.86% 1.69% -24.56%
NOPAT Q/Q Growth
0.00% 0.00% -63.64% -10.86% 1.69% -24.56%
Net Income Q/Q Growth
0.00% 0.00% 69.73% -9.52% 1.56% -24.94%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 10.59% -17.11%
Operating Cash Flow Q/Q Growth
0.00% 0.00% -60.41% 9.74% 7.60% -66.45%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 1.51% 14.81% -75.59%
Invested Capital Q/Q Growth
0.00% 0.00% -64.89% -2,054.28% -297.96% 15.45%
Profitability Metrics
- - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
101.55% 100.02% 100.12% 100.17% 100.19% 100.13%
Interest Burden Percent
66.30% 101.10% 100.01% 96.46% 95.51% 98.15%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
24.26% -367.80% -52.84% -106.23% -147.33% -55.00%
Cash Return on Invested Capital (CROIC)
0.00% -501.62% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
24.26% -367.80% -52.84% -106.95% -148.34% -55.00%
Return on Equity Simple (ROE_SIMPLE)
24.26% -135.54% -62.54% -95.07% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-0.32 -0.95 -5.75 -11 -16 -21
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
20.49% -346.36% -15.97% -27.77% -33.11% -14.46%
Return On Investment Capital (ROIC_SIMPLE)
- - - -69.73% -119.78% -22.14%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-1.70 -24 -8.22 -16 -23 -30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-1.70 -24 -8.22 -16 -23 -30
Valuation Ratios
- - - - - -
Price to Book Value (P/BV)
0.00 0.83 2.42 8.38 4.57 1.87
Price to Tangible Book Value (P/TBV)
0.00 0.83 2.42 8.38 4.57 1.87
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - -
Debt to Equity
-0.87 0.00 0.00 0.00 0.00 0.01
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.01
Financial Leverage
-0.86 -1.02 -1.00 -1.05 -1.19 -1.09
Leverage Ratio
-0.11 1.41 1.06 1.19 1.46 1.19
Compound Leverage Factor
-0.08 1.43 1.06 1.14 1.39 1.17
Debt to Total Capital
-650.19% 0.28% 0.00% 0.00% 0.00% 0.99%
Short-Term Debt to Total Capital
-650.19% 0.28% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.99%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% -1.25% 0.00% 0.00%
Common Equity to Total Capital
750.19% 99.72% 100.00% 101.25% 100.00% 99.01%
Debt to EBITDA
-2.41 0.00 0.00 0.00 0.00 -0.03
Net Debt to EBITDA
-2.18 0.73 0.00 0.00 0.00 3.36
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.03
Debt to NOPAT
-12.91 -0.05 0.00 0.00 0.00 -0.04
Net Debt to NOPAT
-11.67 18.59 0.00 0.00 0.00 4.74
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.04
Altman Z-Score
-32.51 38.93 6.66 16.71 -3.49 8.25
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% -0.69% -0.68% 0.00%
Liquidity Ratios
- - - - - -
Current Ratio
0.10 90.01 11.70 5.32 2.33 10.01
Quick Ratio
0.07 87.33 10.55 4.70 2.04 9.93
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -2.03 -5.07 -10 -13 -20
Operating Cash Flow to CapEx
0.00% -198,167.96% 0.00% -21,830.79% -1,239.31% -3,265.04%
Free Cash Flow to Firm to Interest Expense
0.00 -7.63 -10,204.60 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-3.97 -5.97 -14,906.04 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-3.97 -5.98 -14,906.04 0.00 0.00 0.00
Efficiency Ratios
- - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - -
Invested Capital
-0.68 0.40 -0.28 -1.31 -4.43 -5.68
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 1.08 -0.68 -1.03 -3.12 -1.25
Enterprise Value (EV)
25 -2.64 18 120 43 76
Market Capitalization
21 15 32 137 61 176
Book Value per Share
($1.40) $4.90 $0.94 $0.83 $0.48 $2.79
Tangible Book Value per Share
($1.40) $4.90 $0.94 $0.83 $0.48 $2.79
Total Capital
-0.63 18 13 16 13 95
Total Debt
4.10 0.05 0.00 0.00 0.00 0.93
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.93
Net Debt
3.71 -18 -13 -18 -18 -99
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.05 1.18 0.73
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.03 0.39 0.19 -1.44 -6.17 -9.28
Debt-free Net Working Capital (DFNWC)
-0.64 18 14 16 12 91
Net Working Capital (NWC)
-4.74 18 14 16 12 91
Net Nonoperating Expense (NNE)
0.83 23 2.48 4.30 5.83 8.47
Net Nonoperating Obligations (NNO)
4.05 -18 -13 -18 -18 -99
Total Depreciation and Amortization (D&A)
0.00 0.06 0.00 0.01 0.12 0.36
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 ($6.64) ($0.59) ($0.89) ($0.76) ($0.89)
Adjusted Weighted Average Basic Shares Outstanding
0.00 13.86M 13.89M 17.34M 28.29M 32.97M
Adjusted Diluted Earnings per Share
$0.00 ($6.64) $0.00 ($0.89) ($0.76) ($0.89)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 13.86M 13.90M 17.34M 28.29M 32.97M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($6.64) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 13.86M 13.90M 26.40M 27.72M 52.96M
Normalized Net Operating Profit after Tax (NOPAT)
-0.32 -0.95 -5.75 -11 -16 -21
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - -
EBIT to Interest Expense
-16.72 -90.64 -16,537.12 0.00 0.00 0.00
NOPAT to Interest Expense
-3.12 -3.56 -11,575.98 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-16.72 -90.64 -16,537.12 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-3.12 -3.56 -11,575.98 0.00 0.00 0.00
Payout Ratios
- - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -1.30% -1.50% 0.00% -0.47%

Quarterly Metrics And Ratios for Immix Biopharma

This table displays calculated financial ratios and metrics derived from Immix Biopharma's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
26,396,420.00 26,414,300.00 27,450,479.00 27,507,637.00 27,722,108.00 27,877,293.00 28,834,111.00 33,577,873.00 105,929,098.00 54,411,427.00 71,539,314.00
DEI Adjusted Shares Outstanding
26,396,420.00 26,414,300.00 27,450,479.00 27,507,637.00 27,722,108.00 27,877,293.00 28,834,111.00 33,577,873.00 105,929,098.00 54,411,427.00 71,539,314.00
DEI Earnings Per Adjusted Shares Outstanding
-0.20 -0.17 -0.26 -0.17 -0.16 -0.24 -0.26 -0.32 -0.09 -0.21 -0.19
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-120.86% -25.75% -62.94% 7.95% 16.93% -41.89% -2.15% -118.42% -130.83% -85.68% -110.30%
EBIT Growth
-121.76% -26.39% -63.47% 7.23% 16.23% -42.85% -3.62% -118.43% -130.71% -85.43% -108.10%
NOPAT Growth
-121.76% -26.39% -63.47% 7.23% 16.23% -42.85% -3.62% -118.43% -130.71% -85.43% -108.10%
Net Income Growth
-113.41% -22.45% -64.58% 6.66% 14.79% -50.31% -6.10% -122.11% -122.05% -74.51% -83.60%
EPS Growth
-22.22% 37.50% -4.35% 37.50% 31.82% -46.67% 0.00% -86.67% -20.00% 18.18% 20.83%
Operating Cash Flow Growth
-82.93% -49.52% -30.76% 44.87% 55.97% -1.02% -46.32% -647.16% -483.17% -121.02% -108.40%
Free Cash Flow Firm Growth
-116.67% -9.39% -17.49% 86.59% 147.52% 160.78% 106.01% -1,639.12% -631.23% -557.44% -5,483.10%
Invested Capital Growth
-328.13% 85.46% -1,765.51% -239.15% -749.17% -727.01% -503.32% -28.19% 0.63% 27.62% 26.28%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-3.60% 15.95% -57.52% 32.88% 6.51% -43.56% -13.40% -43.51% 1.20% -15.48% -28.44%
EBIT Q/Q Growth
-3.99% 15.88% -57.26% 32.56% 6.10% -43.45% -14.06% -42.16% 0.82% -15.30% -28.01%
NOPAT Q/Q Growth
-3.99% 15.88% -57.26% 32.56% 6.10% -43.45% -14.06% -42.16% 0.82% -15.30% -28.01%
Net Income Q/Q Growth
-3.41% 17.36% -62.27% 32.69% 5.60% -45.79% -14.54% -40.89% 5.62% -14.58% -20.51%
EPS Q/Q Growth
8.33% 31.82% -60.00% 37.50% 0.00% -46.67% -9.09% -16.67% 35.71% 0.00% -5.56%
Operating Cash Flow Q/Q Growth
-42.93% -37.34% 23.21% 63.43% -14.15% -215.09% -11.22% -86.76% 10.90% -19.42% -4.88%
Free Cash Flow Firm Q/Q Growth
-10.08% -24.07% -7.03% 90.83% 490.01% 58.68% -89.42% -2,755.19% -19.13% -36.64% -24.54%
Invested Capital Q/Q Growth
51.90% 252.59% -216.11% -297.96% -20.44% -12.67% -11.72% 15.45% 6.64% 17.93% -13.78%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.17% 100.23% 100.16% 100.22% 100.22% 100.13% 100.10% 100.11% 100.00% 100.12% 100.00%
Interest Burden Percent
95.21% 93.47% 96.53% 96.27% 96.79% 98.45% 98.90% 98.01% 93.36% 92.67% 87.34%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-93.62% -103.81% -118.50% -147.33% -112.34% -162.04% -182.55% -55.00% -74.47% -34.18% -26.95%
Cash Return on Invested Capital (CROIC)
0.00% -1,975.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-94.37% -103.97% -118.90% -148.34% -113.20% -162.04% -182.55% -55.00% -74.47% -34.18% -26.95%
Return on Equity Simple (ROE_SIMPLE)
-66.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-3.91 -3.29 -5.18 -3.49 -3.28 -4.70 -5.36 -7.63 -7.56 -8.72 -11
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-7.14% -6.26% -10.32% -7.51% -5.86% -11.43% -13.21% -5.23% -4.83% -2.33% -1.56%
Return On Investment Capital (ROIC_SIMPLE)
-13.64% -13.20% -27.86% -26.34% -30.97% -83.59% -58.11% -8.05% -8.87% -3.79% -3.32%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-5.59 -4.70 -7.39 -4.99 -4.68 -6.72 -7.66 -11 -11 -12 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-5.57 -4.68 -7.37 -4.95 -4.62 -6.64 -7.53 -11 -11 -12 -16
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.90 2.19 2.33 4.57 4.85 0.00 7.29 1.87 5.72 2.45 2.22
Price to Tangible Book Value (P/TBV)
2.90 2.19 2.33 4.57 4.85 0.00 7.29 1.87 5.72 2.45 2.22
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 30.63 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.04 0.04 0.06 0.00 0.10 0.21 0.12 0.01 0.01 0.00 0.00
Long-Term Debt to Equity
0.04 0.04 0.06 0.00 0.10 0.21 0.12 0.01 0.01 0.00 0.00
Financial Leverage
-1.01 -0.96 -1.03 -1.19 -1.16 -1.18 -1.30 -1.09 -1.11 -1.04 -1.03
Leverage Ratio
1.21 1.20 1.28 1.46 1.46 1.56 1.75 1.19 1.23 1.09 1.07
Compound Leverage Factor
1.15 1.12 1.24 1.40 1.41 1.53 1.73 1.17 1.15 1.01 0.93
Debt to Total Capital
3.69% 4.18% 5.52% 0.00% 9.36% 17.28% 10.46% 0.99% 1.07% 0.39% 0.26%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
3.69% 4.18% 5.52% 0.00% 9.36% 17.28% 10.46% 0.99% 1.07% 0.39% 0.26%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
-0.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
97.30% 95.82% 94.48% 100.00% 90.64% 82.72% 89.54% 99.01% 98.93% 99.61% 99.74%
Debt to EBITDA
-0.06 -0.05 -0.04 0.00 -0.05 -0.04 -0.04 -0.03 -0.03 -0.02 -0.02
Net Debt to EBITDA
1.47 1.14 0.81 0.00 0.69 0.45 0.63 3.36 2.52 5.64 6.85
Long-Term Debt to EBITDA
-0.06 -0.05 -0.04 0.00 -0.05 -0.04 -0.04 -0.03 -0.03 -0.02 -0.02
Debt to NOPAT
-0.08 -0.07 -0.06 0.00 -0.07 -0.06 -0.06 -0.04 -0.04 -0.03 -0.02
Net Debt to NOPAT
2.10 1.62 1.16 0.00 0.98 0.64 0.89 4.74 3.55 7.97 9.70
Long-Term Debt to NOPAT
-0.08 -0.07 -0.06 0.00 -0.07 -0.06 -0.06 -0.04 -0.04 -0.03 -0.02
Altman Z-Score
5.26 3.72 -0.87 -0.95 -3.21 0.00 -4.39 8.85 24.26 33.24 41.42
Noncontrolling Interest Sharing Ratio
-0.80% -0.15% -0.34% -0.68% -0.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
5.82 7.00 3.47 2.33 1.80 1.23 1.53 10.01 8.76 25.13 33.72
Quick Ratio
5.18 6.14 3.00 2.04 1.71 1.16 1.47 9.93 8.59 24.95 33.55
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-3.01 -3.73 -4.00 -0.37 1.43 2.27 0.24 -6.38 -7.60 -10 -13
Operating Cash Flow to CapEx
-1,267.53% -5,414.40% -1,486.36% -291.08% -2,488.65% -4,160.29% -1,585.63% -6,679.51% -30,250.55% -55,769.16% -10,151.55%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-0.63 0.96 -1.11 -4.43 -5.34 -6.01 -6.72 -5.68 -5.30 -4.35 -4.95
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-0.90 0.44 -1.18 -3.12 -4.71 -6.97 -5.60 -1.25 0.03 1.66 1.77
Enterprise Value (EV)
52 29 22 43 32 0.00 45 76 393 328 404
Market Capitalization
81 52 41 61 47 0.00 60 176 483 561 744
Book Value per Share
$1.06 $0.90 $0.64 $0.48 $0.35 $0.16 $0.29 $2.79 $1.59 $4.21 $4.68
Tangible Book Value per Share
$1.06 $0.90 $0.64 $0.48 $0.35 $0.16 $0.29 $2.79 $1.59 $4.21 $4.68
Total Capital
29 25 19 13 11 5.63 9.23 95 85 230 336
Total Debt
1.06 1.04 1.03 0.00 0.99 0.97 0.97 0.93 0.91 0.89 0.87
Total Long-Term Debt
1.06 1.04 1.03 0.00 0.99 0.97 0.97 0.93 0.91 0.89 0.87
Net Debt
-28 -23 -19 -18 -15 -11 -15 -99 -90 -233 -340
Capital Expenditures (CapEx)
0.30 0.10 0.27 0.51 0.07 0.13 0.37 0.17 0.03 0.02 0.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2.06 -0.55 -3.50 -6.17 -8.45 -9.32 -10 -9.28 -8.84 -7.62 -8.25
Debt-free Net Working Capital (DFNWC)
27 23 16 12 7.47 2.32 5.73 91 82 224 328
Net Working Capital (NWC)
27 23 16 12 7.47 2.32 5.73 91 82 224 328
Net Nonoperating Expense (NNE)
1.42 1.11 1.97 1.32 1.26 1.92 2.22 3.06 2.52 2.84 2.77
Net Nonoperating Obligations (NNO)
-28 -23 -19 -18 -15 -11 -15 -99 -90 -233 -340
Total Depreciation and Amortization (D&A)
0.02 0.02 0.03 0.04 0.06 0.08 0.13 0.09 0.13 0.13 0.12
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.22) ($0.15) ($0.24) ($0.15) ($0.15) ($0.22) ($0.24) ($0.28) ($0.18) ($0.18) ($0.19)
Adjusted Weighted Average Basic Shares Outstanding
23.44M 28.79M 29.42M 28.29M 29.70M 29.98M 31.93M 32.97M 55.37M 63.77M 74.09M
Adjusted Diluted Earnings per Share
($0.22) ($0.15) ($0.24) ($0.15) ($0.15) ($0.22) ($0.24) ($0.28) ($0.18) ($0.18) ($0.19)
Adjusted Weighted Average Diluted Shares Outstanding
23.44M 28.79M 29.42M 28.29M 29.70M 29.98M 31.93M 32.97M 55.37M 63.77M 74.09M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
26.41M 27.45M 27.51M 27.72M 27.88M 28.83M 33.58M 52.96M 54.41M 71.54M 83.81M
Normalized Net Operating Profit after Tax (NOPAT)
-3.91 -3.29 -5.18 -3.49 -3.28 -4.70 -5.36 -7.63 -7.56 -8.72 -11
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.71% -0.47% -0.59% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Immix Biopharma remains a development-stage biotechnology company with no reported revenue in the periods provided. Its financial profile has strengthened significantly since 2024 because of equity financing, but operating losses and cash burn have also increased as the company advances its research programs.

  • Substantial liquidity improvement: As of June 30, 2026, IMMX reported $225.5 million in cash and equivalents, $6.6 million in short-term investments and $2.1 million in long-term investments. This compares with just $15.9 million in cash at the end of the third quarter of 2025.
  • Strong balance-sheet liquidity: Total current assets of $233.8 million substantially exceeded current liabilities of $9.3 million, resulting in an approximate current ratio of 25.1. Total liabilities were only $10.2 million against $239.1 million of assets.
  • Recent financing materially extended the cash runway: IMMX generated $155.3 million from financing activities in the second quarter of 2026. Based on the quarter’s operating cash burn of $11.7 million, the company appears to have significant near-term funding capacity, although future clinical and manufacturing costs could increase materially.
  • Investment income is helping offset losses: Interest and investment income increased from $84,539 in the third quarter of 2025 to $913,663 in the second quarter of 2026, reflecting the company’s larger cash and investment balances.
  • Debt exposure remains limited: Total liabilities declined to $10.2 million in the second quarter from $11.5 million in the first quarter of 2026. Capital lease obligations were less than $1 million, and the company reported no commitments or contingencies in the supplied balance-sheet data.
  • Cash is being actively managed: IMMX purchased $4.5 million of investments and sold or matured $7.2 million during the second quarter. This generated $2.7 million of investing cash flow, but the movements primarily reflect treasury management rather than operating profitability.
  • Research spending remains substantial: Research and development expense was $5.3 million in the second quarter of 2026, down from $6.0 million in the first quarter but above the $2.2 million reported in the second quarter of 2024. Continued R&D spending could support pipeline progress, but it will likely keep cash flow negative.
  • IMMX has not yet generated revenue: Reported revenue and gross profit were zero in each of the supplied income statements, leaving the company dependent on financing and investment income to fund operations.
  • Operating losses are widening: The net loss increased to $11.6 million in the second quarter of 2026 from $10.1 million in the first quarter and $6.6 million in the second quarter of 2025. Quarterly operating expenses reached $12.5 million, including $7.1 million of selling, general and administrative expense and $5.3 million of R&D expense.
  • Ongoing equity financing has diluted shareholders: Common stock increased from $90.9 million in the second quarter of 2025 to $355.0 million in the second quarter of 2026. Weighted-average basic shares outstanding also rose from 29.0 million in the second quarter of 2025 to 63.8 million in the second quarter of 2026, creating meaningful dilution risk as the company continues to fund operations.

Overall, IMMX’s immediate liquidity position is considerably stronger than it was during 2024 and much of 2025. However, the improvement was driven primarily by equity financing rather than revenue growth or internally generated cash. Investors should monitor clinical progress, quarterly operating cash burn, additional financing needs and further increases in the share count.

11/20/26 02:36 PM ETAI Generated. May Contain Errors.

Immix Biopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Immix Biopharma's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Immix Biopharma's net income appears to be on a downward trend, with a most recent value of -$29.44 million in 2025, falling from -$1.15 million in 2020. The previous period was -$21.70 million in 2024. See Immix Biopharma's forecast for analyst expectations on what's next for the company.

Immix Biopharma's total operating income in 2025 was -$29.96 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $29.96 million

Over the last 5 years, Immix Biopharma's total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

In the past 12 quarters, Immix Biopharma's cash and equivalents has ranged from $11.64 million in Q2 2025 to $320.32 million in Q3 2026, and is currently $320.32 million as of their latest financial filing in Q3 2026.

Immix Biopharma had total debt of $933.63 thousand at the end of 2025, compared with none in 2024, and a 77.2% decrease since 2020.

Over the last 5 years, Immix Biopharma's book value per share changed from -1.40 in 2020 to 2.79 in 2025.



Financial statements for NASDAQ:IMMX last updated on 11/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners